PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.99%
R&D growth above 1.5x TRVN's 16.26%. Michael Burry would check for spending discipline.
-4.08%
G&A reduction while TRVN shows 2.56% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
80.19%
Other expenses growth less than half of TRVN's 630.58%. David Dodd would verify if advantage is sustainable.
21.99%
Operating expenses growth above 1.5x TRVN's 13.25%. Michael Burry would check for inefficiency.
21.99%
Total costs growth above 1.5x TRVN's 13.25%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
80.19%
D&A growth above 1.5x TRVN's 9.27%. Michael Burry would check for excessive investment.
32.89%
EBITDA growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-21.99%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
198.65%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
32.68%
Pre-tax income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.68%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
32.51%
EPS growth while TRVN declines. John Neff would investigate advantages.
32.51%
Diluted EPS growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.